home / stock / tsha / tsha quote
Last: | $2.16 |
---|---|
Change Percent: | -1.77% |
Open: | $2.3 |
Close: | $2.16 |
High: | $2.31 |
Low: | $2.14 |
Volume: | 1,942,455 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.16 | $2.3 | $2.16 | $2.31 | $2.14 | 1,942,455 | 07-02-2024 |
$2.26 | $2.38 | $2.26 | $2.3994 | $2.2 | 2,979,223 | 07-01-2024 |
$2.24 | $2.17 | $2.24 | $2.31 | $2.07 | 28,053,032 | 06-28-2024 |
$2.165 | $2.09 | $2.165 | $2.21 | $2.04 | 3,693,423 | 06-27-2024 |
$2.04 | $2.24 | $2.04 | $2.26 | $1.83 | 10,169,941 | 06-26-2024 |
$2.465 | $2.61 | $2.465 | $2.67 | $2.45 | 2,073,971 | 06-25-2024 |
$2.66 | $2.92 | $2.66 | $2.985 | $2.59 | 2,169,960 | 06-24-2024 |
$2.96 | $2.91 | $2.96 | $2.99 | $2.745 | 5,482,231 | 06-21-2024 |
$2.76 | $2.93 | $2.76 | $3.125 | $2.74 | 3,177,769 | 06-20-2024 |
$2.97 | $3.78 | $2.97 | $3.82 | $2.44 | 9,402,862 | 06-19-2024 |
$2.97 | $3.78 | $2.97 | $3.82 | $2.44 | 9,402,862 | 06-18-2024 |
$4.03 | $3.98 | $4.03 | $4.07 | $3.72 | 7,979,071 | 06-17-2024 |
$3.97 | $4.15 | $3.97 | $4.17 | $3.9 | 1,395,246 | 06-14-2024 |
$4.17 | $3.96 | $4.17 | $4.32 | $3.9315 | 2,756,589 | 06-13-2024 |
$3.91 | $3.79 | $3.91 | $4.01 | $3.66 | 1,462,672 | 06-12-2024 |
$3.75 | $3.89 | $3.75 | $3.93 | $3.72 | 1,003,016 | 06-11-2024 |
$3.92 | $3.94 | $3.92 | $4.0044 | $3.84 | 1,005,896 | 06-10-2024 |
$3.95 | $3.8 | $3.95 | $4.015 | $3.775 | 1,303,919 | 06-07-2024 |
$3.86 | $4 | $3.86 | $4.02 | $3.75 | 1,745,547 | 06-06-2024 |
$3.99 | $3.69 | $3.99 | $4 | $3.675 | 1,866,267 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Taysha Gene Therapies Inc. Company Name:
TSHA Stock Symbol:
NASDAQ Market:
Taysha Gene Therapies Inc. Website:
2024-06-26 17:30:03 ET BMO Capital analyst issues OUTPERFORM recommendation for TSHA on June 26, 2024 04:10PM ET. TSHA was trading at $2.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy, 1 - Hol...
DALLAS, June 26, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an ...
DALLAS, June 25, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commen...